[Articles] Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study

Although this study did not meet its primary endpoints, prespecified subgroup analyses of patients with EGFR FISH-positive squamous-cell carcinoma cancers are encouraging and support continued evaluation of anti-EGFR antibodies in this subpopulation.

Source: The Lancet Oncology - November 20, 2017 Category: Cancer & Oncology Authors: Roy S Herbst, Mary W Redman, Edward S Kim, Thomas J Semrad, Lyudmila Bazhenova, Gregory Masters, Kurt Oettel, Perry Guaglianone, Christopher Reynolds, Anand Karnad, Susanne M Arnold, Marileila Varella-Garcia, James Moon, Philip C Mack, Charles D Blanke, F Tags: Articles Source Type: research